Does Rallies show BCAX price targets?

Yes. Rallies tracks BCAX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.

Is BCAX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BCAX. It does not provide personalized investment advice.

BCAX (Bicara Therapeutics Inc. Common Stock) Stock Analysis - Analyst Ratings

Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAX trades at $20.11 with a market cap of $1.27B and a P/E ratio of -8.10. BCAX moved +2.05% today. Year to date, BCAX is +26.82%; over the trailing twelve months it is +35.84%. Its 52-week range spans $7.80 to $28.09. Analyst consensus is strong buy with an average price target of $30.99. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate BCAX?

11 analysts cover BCAX: 0 strong buy, 9 buy, 2 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $30.99.

BCAX Key Metrics

Key financial metrics for BCAX
Metric	Value
Price	$20.11
Market Cap	$1.27B
P/E Ratio	-8.10
EPS	$-2.52
Dividend Yield	0.00%
52-Week High	$28.09
52-Week Low	$7.80
Volume	4.29K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-137.95M
Gross Margin	0.00%

BCAX Analyst Consensus

11 analysts cover BCAX: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $30.99.

Latest BCAX News

Bicara posts $8.3M Q1 net loss, advances BT-11 Phase 1b/2a and BT-12 IND — May 12, 2026
Bicara Secures $161.8M, Holds $539.8M Cash, Q3 Ficerafusp Combo Trial — May 11, 2026
Bicara Therapeutics Launches Phase 3 FORTIFI-HN01 Trial and Raises $161.8M — Mar 30, 2026
Bicara’s Ficera Achieves 54% ORR, BofA Initiates Buy with $35 — Mar 25, 2026
Bicara Sets FORTIFY Trial at 1,500 mg Weekly Dose Versus Pembrolizumab, Mid-2027 Readout Target — Mar 6, 2026

Recent BCAX Insider Trades

Cohlhepp Ryan sold 8.00K (~$162.34K) on May 15, 2026.
Cohlhepp Ryan sold 4.50K (~$91.31K) on May 15, 2026.
Raben David sold 5.50K (~$125.83K) on Apr 27, 2026.

Common questions about BCAX

What do analysts rate BCAX?: 11 analysts cover BCAX: 0 strong buy, 9 buy, 2 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $30.99.
Does Rallies show BCAX price targets?: Yes. Rallies tracks BCAX analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is BCAX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BCAX. It does not provide personalized investment advice.